SIGA Technologies (SIGA) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Entrada Therapeutics (TRDA) has outperformed SIGA Technologies (SIGA) over the past year, losing 57.0% versus a loss of 58.9%. Over five years, SIGA leads with a -71.9% price change compared with -85.0% for TRDA. SIGA Technologies is the larger company by market cap ($172.5 million vs $170.3 million), about 1.0 times the size.
SIGA Technologies converts more of its revenue into profit, with a net margin of 24.6% versus -565.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SIGA | TRDA |
|---|---|---|
| Share price | $2.40 | $4.35 |
| Market cap | $172.45M | $170.30M |
| 1-day change | -9.43% | -6.25% |
| YTD return | -60.72% | -57.68% |
| 1-year return | -58.90% | -56.97% |
| 5-year return | -71.90% | -84.95% |
| P/E ratio (TTM) | 240.00 | — |
| Forward P/E | 5.45 | — |
| EPS (TTM) | $0.01 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $94.57M | $25.42M |
| Revenue growth (YoY) | -31.82% | -87.94% |
| Net income (latest FY) | $23.28M | $-143.75M |
| Gross margin | 68.59% | — |
| Operating margin | 25.06% | -621.13% |
| Net margin | 24.61% | -565.48% |
| 52-week high | $7.11 | $16.45 |
| 52-week low | $2.30 | $4.11 |
| Distance from 52-week high | -66.24% | -73.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +35.42% | +308.05% |
| Average volume | 617.60K | 401.15K |
| Shares outstanding | 71.86M | 39.15M |
| Employees | 49 | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SIGA Technologies is more profitable, keeping 24.6 cents of every revenue dollar as net income versus -565.5 cents for Entrada Therapeutics.
- SIGA Technologies grew revenue faster in its latest fiscal year (-31.82% vs -87.94%).
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
SIGA vs TRDA FAQ
Which is bigger, SIGA Technologies or Entrada Therapeutics?
SIGA Technologies (SIGA) is larger, with a market capitalization of $172.45M compared with $170.30M for Entrada Therapeutics (TRDA).
Which stock has performed better over the past year, SIGA or TRDA?
TRDA returned -56.97% over the past 12 months, compared with -58.90% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are SIGA Technologies and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.